Hossam Sharaf, Moheb Wadie, Noha O Mansour, Mohamed E E Shams
{"title":"Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE-AHF).","authors":"Hossam Sharaf, Moheb Wadie, Noha O Mansour, Mohamed E E Shams","doi":"10.1002/cpt.70540","DOIUrl":"10.1002/cpt.70540","url":null,"abstract":"<p><p>Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active-controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg (N = 55) or acetazolamide 500 mg (N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between-group difference in 72-hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N-terminal pro-B-type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72-hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N-terminal pro-B-type natriuretic peptide at 72 hours (-34.2% vs. -25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short-term reduction in N-terminal pro-B-type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to \"REGBOT: Artificial Intelligence-Driven Compliance Automation for Global Pharmacogenomics Data Sharing (Abstract PS02.38)\".","authors":"","doi":"10.1002/cpt.70556","DOIUrl":"10.1002/cpt.70556","url":null,"abstract":"","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Pharmacology in Transgender Medicine: What Gaps Remain?","authors":"Lauren R Cirrincione","doi":"10.1002/cpt.70549","DOIUrl":"10.1002/cpt.70549","url":null,"abstract":"<p><p>Mechanistic information is limited about the effects of gender-affirming hormone therapy and the unique factors that influence the absorption, distribution, metabolism, and excretion properties of medications across therapeutic classes for transgender people. Opportunities exist to address knowledge gaps in transgender medicine using well-designed probe substrate studies, endogenous biomarkers of drug-metabolizing enzymes and transporters, and real-world data to identify and address factors that contribute to interindividual variability in drug disposition for transgender people across the life course.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing.","authors":"Daniel Eisenkraft Klein, Aaron S Kesselheim","doi":"10.1002/cpt.70538","DOIUrl":"10.1002/cpt.70538","url":null,"abstract":"<p><p>This analysis characterizes the magnitude, timing, and keyword targeting strategies of the Pharmaceutical Research and Manufacturers of America's (PhRMA) pay-per-click advertising expenditures and their relation to major drug pricing policy developments (2019-2025). Pay-per-click advertising allows advertisers to purchase prominent placement in search engine results, allowing their content to appear above organic results when users search for specific terms. We extracted pay-per-click advertising data from Semrush, a commercial digital marketing intelligence platform, for the domain www.phrma.org from February 2019 through December 2025. We classified keywords into mutually exclusive categories using a specificity-based pattern-matching algorithm and categorized landing-page URLs by content theme using URL string matching. We analyzed monthly spending against a timeline of major legislative and regulatory events. PhRMA spent an estimated $58.8 million across 283,517 keyword instances, generating 17.1 million paid visits to phrma.org and its subdomains. Insurance and health plan keywords dominated spending ($32.4 million; 55.1%), including general and non-health insurance terms. Nearly half of total expenditures (47.5%; $27.9 million) drove traffic to pages classified as criticizing pharmacy benefit managers. Monthly spending showed little linear association with the selected Google Trends index (r = -0.05), but spending surged around well-publicized US legislative and regulatory actions, peaking at $4.8 million in May 2023; March-September 2023 accounted for 36.5% of total spending. Overall, PhRMA pay-per-click spending surges coincided with major US drug pricing policy developments.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mattie E Hartauer, Raeanne M Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B Tiley, John K Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L R Brouwer
{"title":"Integrated assessment of rifampicin-mediated induction of transporters and drug-metabolizing enzymes in a long-term human liver tissue chip system.","authors":"Mattie E Hartauer, Raeanne M Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B Tiley, John K Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L R Brouwer","doi":"10.1002/cpt.70418","DOIUrl":"10.1002/cpt.70418","url":null,"abstract":"<p><p>Rifampicin is a prototypical clinical inducer used in drug-drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin-mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug-metabolizing enzymes (DMEs), particularly at the protein level. In this study, we characterized a liver tissue chip (LTC) as a new approach methodology (NAM) for long-term transporter- and DME-mediated induction risk assessment. Transporter-certified® cryopreserved primary human hepatocytes from three donors were cultured in the LTC under recirculating flow with or without 10 μM rifampicin for 7 days. The LTC facilitated simultaneous mRNA-protein quantification for transporters and mRNA-protein-activity profiling for cytochrome P450s (CYPs) within individual chips across treatment and control conditions. In addition, extracellular bile acid profiling and intracellular rifampicin concentrations were measured by LC-MS/MS. Rifampicin induced multiple transporters and enzymes at the protein level, including organic anion transporting polypeptide (OATP)2B1, P-glycoprotein, CYP3A4, CYP2C19, and uridine 5'-diphospho-glucuronosyltransferase (UGT)1A4. Induction patterns differed between transporter mRNA and protein in many cases, suggesting regulatory mechanisms beyond PXR-mediated activation. Matched mRNA-protein-activity measurements of five CYP enzymes also revealed discrepancies in rifampicin-mediated induction magnitude. Rifampicin altered bile acid composition, increasing taurine-conjugated bile acids and inducing bile acid-related genes. Measured intracellular rifampicin concentrations differed substantially from experimentally employed media concentrations. Overall, these findings demonstrate that the LTC enables integrated assessment of mRNA, protein, and activity measurements in addition to bile acid profiles and intracellular drug exposure, which may improve mechanistic understanding of induction processes.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1368-1378"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren A R Tompkins, Amanda Poliseno, Airlie Ward, Edward P Browne, Cassandra Gilbert, Craig Sykes, Angela D M Kashuba, Mackenzie L Cottrell
{"title":"Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV-1 Latency Reversal.","authors":"Lauren A R Tompkins, Amanda Poliseno, Airlie Ward, Edward P Browne, Cassandra Gilbert, Craig Sykes, Angela D M Kashuba, Mackenzie L Cottrell","doi":"10.1002/cpt.70488","DOIUrl":"10.1002/cpt.70488","url":null,"abstract":"<p><p>Romidepsin (RMD), an FDA-approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency-reversing activity in vitro but has yielded suboptimal outcomes in kick-and-kill HIV-cure trials when administered as a 5 mg/m<sup>2</sup> infusion. We hypothesized that distinct pharmacokinetic targets exist between the pharmacodynamic goals of cytotoxicity for cancer therapy and latency reversal for HIV cure. To address this question, we designed an empirical modeling framework incorporating patient pharmacokinetics as a New Approach Methodology. Using clonal- and primary cell models of HIV-1 latency with readouts for different stages of latency-reversing activity, we performed exposure-response and dose-fractionation studies to define pharmacokinetic drivers of efficacy in latency, then designed tailored dosing strategies to meet these targets in static- and dynamic-culture systems, including a hollow-fiber model. Across all systems, the only consistent pharmacokinetic parameter driving latency-reversing activity, was RMD exposure time, with maximal activity achieved in cells exposed to ~4-6 ng/mL RMD for ≥ 20 hours (AUCs of ~80-120 ng*hour/mL). With current clinical-dosing strategies achieving AUCs of 240-600 ng*hour/mL, the same outcome occurred only when RMD concentrations greatly exceeded a cytotoxicity threshold, suggesting response was a byproduct of cytotoxic processes rather than targeted latency reversal. These findings indicate that conventional oncologic dosing strategies for RMD might not be directly applicable to HIV-1 latency reversal, offering a mechanistic explanation for suboptimal clinical outcomes. We provide proof-of-concept for RMD's limited clinical efficacy and propose a \"low and slow\" dosing strategy targeting time-driven, toxicity-minimized drug exposure, demonstrating how in vitro pharmacokinetic/pharmacodynamic investigations applying clinical pharmacokinetic data may inform dose optimization for clinical trials of latency reversal.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1414-1426"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bailey M Tibben, Maud Maillard, Victoria M Pratt, Ann M Moyer, Debbie M Figueroa, Michelle Whirl-Carrillo, Andrea Gaedigk, Gabriele Stocco, Matthias Schwab, Kelly E Caudle, Jun J Yang
{"title":"Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel.","authors":"Bailey M Tibben, Maud Maillard, Victoria M Pratt, Ann M Moyer, Debbie M Figueroa, Michelle Whirl-Carrillo, Andrea Gaedigk, Gabriele Stocco, Matthias Schwab, Kelly E Caudle, Jun J Yang","doi":"10.1002/cpt.70433","DOIUrl":"10.1002/cpt.70433","url":null,"abstract":"<p><p>The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles. These genes are critical for the metabolism of thiopurines, which are widely used in the treatment of cancer and autoimmune disorders. Standardized allele function assignment is essential for predicting metabolizer phenotypes and pharmacogenetics-guided thiopurine dosing. The work presented here includes the first designation of decreased function alleles for both TPMT and NUDT15, reflecting new clinical data that demonstrate partial loss of enzymatic activity and reduced dose tolerance. The panel also reclassified several alleles previously assigned uncertain or unknown function. The functional assignments were informed by a standardized framework incorporating clinical data, such as thiopurine tolerance and toxicity, as well as in vitro protein activity, ex vivo enzymatic measurements, and in silico variant effect prediction tools. These updates enhance the precision of genotype-to-phenotype mapping and support more personalized thiopurine therapy across diverse patient populations.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1427-1437"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13446156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert
{"title":"Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model.","authors":"Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert","doi":"10.1002/cpt.70439","DOIUrl":"10.1002/cpt.70439","url":null,"abstract":"<p><p>Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ-64281802) is a pan-serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV-3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two-compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV-3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E<sub>max</sub> relationship with average mosnodenvir concentration at steady state (C<sub>avg,ss</sub>) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV-3 in this CHIM was estimated at 21.7, and the typical C<sub>avg,ss</sub> required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic-antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1379-1388"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13454417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abigail K Mayo, James J Beaudoin, Jeffrey L Woodhead, Paul B Watkins, Kim L R Brouwer
{"title":"Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Abigail K Mayo, James J Beaudoin, Jeffrey L Woodhead, Paul B Watkins, Kim L R Brouwer","doi":"10.1002/cpt.70355","DOIUrl":"10.1002/cpt.70355","url":null,"abstract":"<p><p>Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100-250 mg). OCA was also evaluated as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) but was not approved by the FDA due to liver safety concerns. In this in silico study, we investigated mechanisms of OCA-associated liver injury in virtual healthy and MASLD populations receiving supratherapeutic and therapeutic (10-25 mg) doses, respectively. OCA and metabolite exposures in plasma, sinusoidal blood, liver, and gut compartments were simulated using a physiologically based pharmacokinetic model. In the virtual MASLD population, exposures were increased 2-, 5-, and 10-fold in plasma, sinusoidal, and/or liver compartments relative to baseline. Mechanistic parameters relevant to OCA-mediated liver injury, including bile acid transporter inhibition and mitochondrial dysfunction, were incorporated into the DILIsym model. Predicted liver injury was reported as evaluation of drug-induced serious hepatotoxicity (eDISH) plots, and elevations in alanine aminotransferase, aspartate aminotransferase, and total hepatic bile acids. DILIsym simulations recapitulated liver biomarker elevations observed at supratherapeutic OCA doses in healthy subjects and predicted biomarker increases in the MASLD population under conditions of 5- and 10-fold increased exposures relevant to this population. Bile acid transporter inhibition alone reproduced simulated biomarker elevations, whereas mitochondrial uncoupling alone predicted increased biomarkers only at the highest exposures. Results suggest that DILIsym modeling would have predicted the liver safety concerns that led to withdrawal of OCA from the US market.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1358-1367"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148300327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Machine Learning Model Predicts Clinical Adverse Events of Small Molecule Kinase Inhibitors in Cancer Patients Using On-/Off-Target Engagement and Tissue Selectivity.","authors":"Natalie M Jusko, Albert Cao, Duxin Sun","doi":"10.1002/cpt.70343","DOIUrl":"10.1002/cpt.70343","url":null,"abstract":"<p><p>Adverse events (AEs) of small molecule kinase inhibitors (SMKIs) at therapeutic doses in cancer patients are largely unpredictable in phase I-III studies and clinical use, despite extensive preclinical toxicity testing under good laboratory practice conditions. To address this gap, we developed a machine learning (ML) framework to predict the occurrence and time to onset of clinical AEs caused by SMKIs using on-/off-target engagement and tissue/cell selectivity. The analysis included 1939 unique AEs from 3,433 patients treated with 16 SMKIs. On-/off-target engagement was evaluated by linking the inhibition (Ki) constants and expression of 442 kinase targets to SMKI exposure, expressed as dose-normalized AUC across plasma and 36 tissues. For each AE, we constructed random survival forest models composed of ensembles of binary decision trees, evaluated predictive accuracy using the concordance index, and applied variable importance (VIMP) measures to identify kinase targets potentially responsible for tissue-specific AEs. The final models successfully predict the most common AEs (rash, nausea, fatigue, headache) along with the most severe hematological AEs (neutropenia, leukopenia, lymphopenia, thrombocytopenia, anemia). VIMP analyses highlighted previously unrecognized kinases potentially involved in tissue-specific AE profiles. External validation using data from a Phase II neratinib monotherapy trial demonstrated strong model performance, yielding Pearson correlation coefficients (PCCs) ≥ 0.87 between predicted and observed AE incidences. These findings show that integrating exposure, on-/off-target engagement, and tissue-specific selectivity enables robust prediction of the likelihood of SMKI-associated AEs for both blood- and organ-related toxicities, offering a scalable approach at both the patient- and population-level.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1348-1357"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}